Trials / Approved For Marketing
Approved For MarketingNCT01724580
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Conditions
- Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
- Juvenile Dermatomyositis (JDM)
- Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)
- Aicardi-Goutières Syndrome (AGS)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Administered orally |
Timeline
- First posted
- 2012-11-12
- Last updated
- 2025-01-17
Locations
3 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT01724580. Inclusion in this directory is not an endorsement.